These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20837824)

  • 21. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
    Green RC; Schneider LS; Amato DA; Beelen AP; Wilcock G; Swabb EA; Zavitz KH;
    JAMA; 2009 Dec; 302(23):2557-64. PubMed ID: 20009055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
    Liu J; Wang LN; Jia JP
    Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.
    Koch G; Motta C; Bonnì S; Pellicciari MC; Picazio S; Casula EP; Maiella M; Di Lorenzo F; Ponzo V; Ferrari C; Scaricamazza E; Caltagirone C; Martorana A
    JAMA Netw Open; 2020 Jul; 3(7):e2010372. PubMed ID: 32667654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.
    Dixon AE; Subramanian M; DeSarno M; Black K; Lane L; Holguin F
    Respir Res; 2015 Nov; 16():143. PubMed ID: 26610598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
    Kaiser CC; Shukla DK; Stebbins GT; Skias DD; Jeffery DR; Stefoski D; Katsamakis G; Feinstein DL
    J Neuroimmunol; 2009 Jun; 211(1-2):124-30. PubMed ID: 19446890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.
    Chen DL; Huang HJ; Byers DE; Shifren A; Belikoff B; Engle JT; Arentson E; Kemp D; Phillips S; Scherrer DE; Fujiwara H; Spayd KJ; Brooks FJ; Pierce RA; Castro M; Isakow W
    PLoS One; 2018; 13(2):e0191783. PubMed ID: 29414995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.
    Boggild AK; Krudsood S; Patel SN; Serghides L; Tangpukdee N; Katz K; Wilairatana P; Liles WC; Looareesuwan S; Kain KC
    Clin Infect Dis; 2009 Sep; 49(6):841-9. PubMed ID: 19673614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
    Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
    JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
    Jain R; Osei K; Kupfer S; Perez AT; Zhang J
    Pharmacotherapy; 2006 Oct; 26(10):1388-95. PubMed ID: 16999648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
    Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S
    Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
    Ott BR; Blake LM; Kagan E; Resnick M;
    J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.